Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 13c

August 11, 2016 8:06 AM EDT
Get Alerts BCLI Hot Sheet
Trade BCLI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.05), $0.13 better than the analyst estimate of ($0.18).

Second Quarter 2016 and Recent Highlights

  • Announced positive topline results from U.S. Phase 2 randomized, placebo controlled study of NurOwn in patients with ALS.
    • Study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated.
    • NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit.
    • Response rates (based on ALSFRS-R responder analysis) were higher in NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks.
    • Further evidence of biological effect was demonstrated by the increased levels of growth factors in the cerebrospinal fluid and decreased inflammatory markers observed after two weeks.
    • Results will be used to help determine the study population and design for a registration study investigating multiple doses of NurOwn in ALS.
    • Phase 2 study was conducted at three sites in the U.S: Massachusetts General Hospital, UMass Medical School and the Mayo Clinic.
  • Company was awarded $1.5 million in non-dilutive funding from Israel's Office of the Chief Scientist.
  • Mr. Chaim Lebovits, CEO, moderated a round table session on Brainstorm's NurOwn proprietary technology at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment